

Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – September 9, 2026 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_eBUt3qLzSkycOdDyUyZx5g

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 910 6408 1365

Passcode: 44589980

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.
- In lieu of speaking at the DUR Board meeting, written correspondence by members or providers may be submitted to DURPublicComment@okhca.org. Other written correspondence is not permitted.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. July 8, 2026 DUR Board Meeting Minutes
- B. July 8, 2026 DUR Board Recommendations Memorandum
- C. August 5, 2026 DUR Board Recommendations Memorandum

Non-presentation items reviewed by Dr. Grimes, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for August 2026
- B. Medication Coverage Activity for August 2026

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Utilization Update – See Appendix C

- A. Introduction
- B. Mailing Summary
- C. Mailing Results
- D. DPP-4 Inhibitor Utilization in the SoonerCare Population FY25 to FY26

- E. Conclusions
- F. Recommendations

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

6. Action Item – Vote to Prior Authorize Enbumyst™ (Bumetanide Nasal Spray), Lasix® ONYU (Furosemide On-Body Infusor), and Myqorzo™ (Aficamten) and Update the Approval Criteria for the Heart Failure (HF) Medications – See Appendix D

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Dorsey, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Leqembi Iqlik® (Lecanemab-irmb) – See Appendix E

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Awiqli® (Insulin Icodec-abae), Glipizide 15mg Tablet, Kirsty™ (Insulin Aspart-xjhz), and Langlara™ (Insulin Glargine-aldy) and Update the Approval Criteria for the Anti-Diabetic Medications and Kerendia® (Finerenone) – See Appendix F

- A. Market News and Updates
- B. Awiqli® (Insulin Icodec-abae) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

9. Action Item – Vote to Prior Authorize Jobevne™ (Bevacizumab-nwgd) – See Appendix G

- A. Market News and Updates
- B. Cost Comparison: Bevacizumab Products
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

10. Action Item – Vote to Prior Authorize Modeyso™ (Dordaviprone) and Vistogard® (Uridine Triacetate) and Update the Approval Criteria for the Miscellaneous Cancer Medications – See Appendix H

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

11. Action Item – Vote to Update the Approval Criteria for the Iron Products – See Appendix I

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

12. Action Item – Vote to Update the Approval Criteria for the Iron Chelating Agents – See Appendix J

- A. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

13. Action Item – Vote to Prior Authorize Amcinonide 0.1% Ointment and Update the Approval Criteria for the Topical Corticosteroids – See Appendix K

- A. Market News and Updates
- B. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

14. Action Item – Vote to Prior Authorize Contempo™ (Fosfomycin for Injection), Doxycycline Hyclate 75mg Capsule, and Orlynvah™ (Sulopenem Etzadroxil/Probenecid) and Update the Approval Criteria for the Various Systemic Antibiotics – See Appendix L

- A. Market News and Updates
- B. Orlynvah™ (Sulopenem Etzadroxil/Probenecid) Product Summary
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Dorsey, Dr. Haymore, Chairman:

15. Action Item – Vote to Prior Authorize Zycubo® (Copper Histidinate) – See Appendix M

- A. Market News and Updates
- B. Zycubo® (Copper Histidinate) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

16. Action Item – Vote to Prior Authorize Morphine Oral Solution Syringes and Tapentadol Tablet, Extended-Release (ER) Tablet, and Oral Solution and Update the Approval Criteria for the Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications – See Appendix N

- A. Market News and Updates
- B. Cost Comparisons
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

17. Action Item – Annual Review of Cystic Fibrosis (CF) Medications – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of CF Medications
- C. Prior Authorization of CF Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of CF Medications

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

18. Action Item – Annual Review of Amyloidosis Medications – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Amyloidosis Medications
- C. Prior Authorization of Amyloidosis Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Amyloidosis Medications

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

19. Action Item – Annual Review of Bladder Control Medications – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of Bladder Control Medications
- C. Prior Authorization of Bladder Control Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Bladder Control Medications

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

20. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Beizray™ (Docetaxel), Beizray™ Kit (Docetaxel/Albumin), Docivyx™ (Docetaxel), Inluriyo™ (Imlunestrant), and Veppanu™ (Vepdegestrant) – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of Breast Cancer Medications
- C. Prior Authorization of Breast Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. Cost Comparison: Trastuzumab Products
- G. College of Pharmacy Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

21. Annual Review of Various Ophthalmic Medications and 30-Day Notice to Prior Authorize Epioxa® HD/Epioxa® (Riboflavin 5'-Phosphate Ophthalmic Solution) and Lumvoa® (Veligrotug-vvze) – See Appendix S

- A. Current Prior Authorization Criteria
- B. Utilization of Various Ophthalmic Medications
- C. Prior Authorization of Various Ophthalmic Medications
- D. Market News and Updates
- E. Lumvoa® (Veligrotug-vvze) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Various Ophthalmic Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

22. Annual Review of Antihistamine Medications (Systemic) and 30-Day Notice to Prior Authorize Cetirizine Oral Solution Unit Dose Cups (UDCs) – See Appendix T

- A. Current Prior Authorization Criteria
- B. Utilization of Systemic Antihistamine Medications
- C. Prior Authorization of Systemic Antihistamine Medications
- D. Market News and Updates
- E. Cost Comparison: Cetirizine Products
- F. College of Pharmacy Recommendations
- G. Utilization Details of Systemic Antihistamine Medications

Non-presentation items reviewed by Dr. Dorsey, Dr. Haymore, Chairman:

23. Annual Review of Benign Prostatic Hyperplasia (BPH) Medications – See Appendix U

- A. Current Prior Authorization Criteria
- B. Utilization of BPH Medications
- C. Prior Authorization of BPH Medications
- D. College of Pharmacy Recommendations
- E. Utilization Details of BPH Medications

Non-presentation items reviewed by Dr. Grimes, Dr. Haymore, Chairman:

24. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix V

Non-presentation items reviewed by Dr. Adams, Dr. Haymore, Chairman:

25. Future Business* (Upcoming Product and Class Reviews)

- A. Anemia Medications
- B. Anticoagulants and Platelet Aggregation Inhibitors
- C. Constipation and Diarrhea Medications
- D. Fibromyalgia Medications
- E. Myeloproliferative Neoplasm (MPN) Medications
- F. Targeted Immunomodulator Agents

*Future product and class reviews subject to change.

26.Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.